Akt inhibitors such as MK2206 and GDC0068 have been tested in clinical trials; however, severe side effects were experienced and substantial tumour shrinkage was generally not observed (Saura et al., 2017; Xing et al., 2019; Yap et al., 2011). Here, AKT1 is linked to neoplasm.